Literature DB >> 18521559

[Imaging before and after uterine artery embolization].

T J Kröncke1.   

Abstract

Percutaneous catheter-based embolization treatment of symptomatic uterine fibroids has evolved into the most widely used alternative therapeutic approach to surgical treatment worldwide. Uterine artery embolization (UAE) induces infarction of leiomyomas, resulting in ischemic necrosis, hyaline degeneration, and size reduction with resolution of associated symptoms. Published experience suggests that UAE is an effective and reliable option for treating uterine fibroids with high patient satisfaction.Magnetic resonance imaging (MRI) is superior to ultrasonography for determining the site, size and number of fibroids, which is important for establishing the indication for UAE. Other potential advantages of MRI include the option of performing MR angiography (MRA) and obtaining contrast-enhanced images for monitoring the outcome of UAE and assessing possible complications after UAE.

Entities:  

Mesh:

Year:  2008        PMID: 18521559     DOI: 10.1007/s00117-008-1686-x

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  35 in total

1.  Uterine artery embolization of symptomatic uterine fibroida . Initial success and short-term results.

Authors:  P E Andersen; N Lund; P Justesen; T Munk; B Elle; C Floridon
Journal:  Acta Radiol       Date:  2001-03       Impact factor: 1.990

2.  Comparison of MRI and sonography in the preliminary evaluation for fibroid embolization.

Authors:  Audrey L Spielmann; Ciaran Keogh; Bruce B Forster; Michael L Martin; Lindsay S Machan
Journal:  AJR Am J Roentgenol       Date:  2006-12       Impact factor: 3.959

3.  Accuracy of magnetic resonance imaging and transvaginal ultrasonography in the diagnosis, mapping, and measurement of uterine myomas.

Authors:  Margit Dueholm; Erik Lundorf; Estrid S Hansen; Susanne Ledertoug; Frede Olesen
Journal:  Am J Obstet Gynecol       Date:  2002-03       Impact factor: 8.661

4.  Complications after uterine artery embolization for leiomyomas.

Authors:  James B Spies; Amy Spector; Antoinette R Roth; Chandra M Baker; Lauren Mauro; Kerry Murphy-Skrynarz
Journal:  Obstet Gynecol       Date:  2002-11       Impact factor: 7.661

5.  Uterine artery embolization for pedunculated subserosal fibroids.

Authors:  Tetsuya Katsumori; Kentarou Akazawa; Tadashi Mihara
Journal:  AJR Am J Roentgenol       Date:  2005-02       Impact factor: 3.959

6.  Symptomatic fibroleiomyomata: MR imaging of the uterus before and after uterine arterial embolization.

Authors:  R C Jha; S M Ascher; I Imaoka; J B Spies
Journal:  Radiology       Date:  2000-10       Impact factor: 11.105

Review 7.  Imaging manifestations of complications associated with uterine artery embolization.

Authors:  Yuri Kitamura; Susan M Ascher; Cirrelda Cooper; Sandra J Allison; Reena C Jha; Pamela A Flick; James B Spies
Journal:  Radiographics       Date:  2005-10       Impact factor: 5.333

8.  Uterine artery embolization for treatment of leiomyomata: long-term outcomes from the FIBROID Registry.

Authors:  Scott C Goodwin; James B Spies; Robert Worthington-Kirsch; Eric Peterson; Gaylene Pron; Shuang Li; Evan R Myers
Journal:  Obstet Gynecol       Date:  2008-01       Impact factor: 7.661

9.  [Role of magnetic resonance imaging (MRI) in establishing the indication for, planning, and following up uterine artery embolization (UAE) for treating symptomatic leiomyomas of the uterus].

Authors:  T J Kröncke; B Hamm
Journal:  Radiologe       Date:  2003-08       Impact factor: 0.635

10.  Does pelvic magnetic resonance imaging differentiate among the histologic subtypes of uterine leiomyomata?

Authors:  L B Schwartz; M Zawin; M L Carcangiu; R Lange; S McCarthy
Journal:  Fertil Steril       Date:  1998-09       Impact factor: 7.329

View more
  1 in total

1.  Diffusion-weighted imaging in uterine artery embolisation: do findings correlate with contrast enhancement and volume reduction?

Authors:  G Ananthakrishnan; G Macnaught; L Hinksman; H Gilmour; K P Forbes; J G Moss
Journal:  Br J Radiol       Date:  2012-08-16       Impact factor: 3.039

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.